EGFR and neoplasm: These authors made the logical hypothesis that gefitinib leading to G1 growth arrest of EGFR-dependent tumour cells may, following continuous administration, attenuate the effects of tubulin inhibitors – such as paclitaxel – which act primarily during mitosis.